Table 4.

Results of univariate and multivariate associations between potential risk factors and death due to all causes

Potential Risk Factors	Death − (n = 119)	Death + (n = 8)	Univariate Analysis	Multivariate Analysis
			P-value	HR (95%CI)	P-value
Pretreatment PSA Level			0.716	-	NS
<10 ng/mL	78 (65.6%)	6 (75 %)
≥10 ng/mL	41 (34.4%)	2 (25 %)
Age			0.006	7.0 (1.5-31.5)	0.012
<70 y	62 (52.1%)	0 (0%)
≥70 y	57 (47.9%)	8 (100%)
Tumor Stage			0.178	-	NS
T1b-T1c	57 (47.9%)	2 (25%)
T2a	45 (37.8%)	3 (37.5%)
T2b	11 (9.2%)	2 (25%)
T2c	6 (5.1%)	1 (12.5%)
Gleason Score			0.616	-	NS
≤6	16 (13.5%)	0 (0%)
7 (3 + 4)	23 (19.3%)	1 (12.5%)
7 (4 + 3)	38 (31.9%)	2 (25%)
≥8	42 (35.3%)	5 (62.5%)
% Positive Biopsy Cores			1.000	-	NS
<50%	79 (66.4%)	5 (62.5%)
≥50%	40 (33.6%)	3 (37.5%)
Perineural Invasiona			0.082	-	NS
Positive	68/97 (70.1%)	2/6 (33.3%)
Negative	29/97 (29.9%)	4/6 (66.7%)
Risk Classificationb			0.008	-	NS
Intermediate 1 NCCN risk factor	55 (46.2%)	0 (0%)
Intermediate >1 NCCN risk factor	19 (16%)	1 (12.5%)
High-risk	45 (37.8%)	7 (87.5%)
PSA Nadira			0.628	-	NS
<1 ng/mL	90/112 (80.4%)	5/7 (71.4%)
≥1 ng/mL	22/112 (19.6%)	2/7 (28.6%)
Biochemical Failure			0.041	-	NS
No	99 (83.2%)	4 (50%)
Yes	20 (16.8%)	4 (50%)
Metastasis			0.002	10.4 (2.6-42.7)	0.001
No	112 (94.1%)	4 (50%)
Yes	7 (5.9%)	4 (50%)

CI = confidence interval, HR = hazard ratio, NCCN = National Comprehensive Cancer Network; NS = non-significant; PSA = prostate-specific antigen.

^aNot available for all patients. Group denominators are shown.

^bIntermediate >1 NCCN risk factor and high-risk patients were analyzed combined.